Funding for Medical Research
and Clinical Trials
and Clinical Trials
Funding Details for Alzheimers/Dementia/Aging
Use the contact information shown for the organization to apply for the funding.
Please notify CenTrial of any offer is incorrect or has expired.
Please notify CenTrial of any offer is incorrect or has expired.
Alzheimer's disease Neuronal lossVascular injury and blood-brain barrier integrityMitochondria and metabolic functionProtein misfoldingOxidative stressWhite matter changesLewy body dementiaOther novel targets supported by compelling biological rationale and connection to disease
Alzheimer’s Drug Discovery Foundation (ADDF)
Type of Organization: Foundation
Email Address: grants@alzdiscovery.org
Funds Available for Clinical Trials: ✗ Research: ✔
Academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
Biotechnology companies. Existing companies and new startups are both eligible.
NOTE: Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).
Other info: The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.
For scientific inquiries, please contact:
Meriel Owen, PhD, Associate Director, Scientific Affairs
mowen@alzdiscovery.org
Alzheimer’s Drug Discovery Foundation (ADDF)
Type of Organization: Foundation
Email Address: grants@alzdiscovery.org
Funds Available for Clinical Trials: ✗ Research: ✔
Funding Details
Requirements: Funding is open to researchers and clinicians worldwide at:Academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
Biotechnology companies. Existing companies and new startups are both eligible.
NOTE: Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).
Other info: The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.
For scientific inquiries, please contact:
Meriel Owen, PhD, Associate Director, Scientific Affairs
mowen@alzdiscovery.org